FDA panel backs proposed J&J psoriasis drug
SILVER SPRING, Maryland (Reuters) - Johnson & Johnson's experimental drug ustekinumab should be approved for treating adults with moderate or severe psoriasis, a U.S. advisory panel unanimously ruled on Tuesday.
<p><img src="http://feeds.feedburner.com/~a/reuters/healthNews?i=pOu1zf" border="0"></img> (http://feeds.feedburner.com/~a/reuters/healthNews?a=pOu1zf)</p><div class="feedflare">
<img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=jFgdJI" border="0"></img> (http://feeds.feedburner.com/~f/reuters/healthNews?a=jFgdJI) <img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=zuP4Qi" border="0"></img> (http://feeds.feedburner.com/~f/reuters/healthNews?a=zuP4Qi) <img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=mGbNOi" border="0"></img> (http://feeds.feedburner.com/~f/reuters/healthNews?a=mGbNOi)
</div><img src="http://feeds.feedburner.com/~r/reuters/healthNews/~4/314093387" height="1" width="1"/>
http://feeds.feedburner.com/~r/reuters/healthNews/~3/314093387/idUSN1738527120080617